BridgeBio Pharma, Inc.
NASDAQ:BBIOBiotechnology
+$0.75 today
- Market cap
- $15.20B
- Beta
- 0.97
- P/E (TTM)
- -18.1
- EPS (TTM)
- -$3.73
Volume 3.55M
Average 2.49M
BBIO Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
BridgeBio Pharma, Inc.NASDAQ: BBIO
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization declines year over year
Q2 FY2026 depreciation & amortization of $1.05M fell 20.0% year over year, behind the -7.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 11.2% from the prior quarter. Over 3 fiscal years it compounded at -7.1% a year.
Context
- Depreciation & amortization amounted to 1.1% of revenue in FY2025, down 1.7 pp from a year earlier.
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -20.0% toward the trailing-twelve-month pace of -7.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 5.43M USD
- Year-over-year change
- -10.6%
- 4-year CAGR
- -1.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.43M | -10.6% |
| FY2024 | 2024-12-31 | 6.08M | -6.5% |
| FY2023 | 2023-12-31 | 6.49M | -4.1% |
| FY2022 | 2022-12-31 | 6.77M | +15.9% |
| FY2021 | 2021-12-31 | 5.84M | — |
Depreciation & Amortization vs competitors
How BBIO compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -7.9% is the 8th highest of 11, against a peer median of +1.3%.
- Depreciation & amortization amounts to 0.7% of revenue for BBIO, versus a peer median of 6.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $244.53B USD | +295495.6% | -7.9% | 23.8% | |
| LTM Jun 2026 | $55.3M USD | +97.1% | -33.0% | 5.5% | |
| LTM Jun 2026 | $54.76M USD | -3.1% | +7.8% | 1.1% | |
| LTM Sep 2026 | $52.78M USD | -3.5% | +43.1% | 8.1% | |
| LTM Sep 2026 | $28.19M USD | +36.7% | +0.9% | 2.9% | |
| LTM Sep 2026 | €18.33M EUR | +5.7% | -1.8% | 1.5% | |
| LTM Mar 2026 | $13.62M USD | -61.8% | +24.3% | 2.0% | |
| LTM Jun 2026 | $13.14M USD | +17.5% | +12.6% | 364.7% | |
| LTM Jun 2026 | $5.07M USD | -7.9% | -7.1% | 0.7% | |
| LTM Mar 2026 | $2.16M USD | -28.6% | -14.3% | 10.8% | |
| LTM Sep 2026 | $1.32M USD | -19.2% | -17.8% | 230.7% | |
| Peer median (excluding BBIO) | — | +1.3% | -0.5% | 6.8% | |
Competitors are the stored peer set for BBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (586.45M) | (484.65M) | (643.2M) | (543.35M) | (724.93M) |
| Depreciation & Amortization | 5.84M | 6.77M | 6.49M | 6.08M | 5.43M |
| Deferred Income Tax | (30.93M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 99.51M | 91.56M | 0 | 95.8M | 133.02M |
| Change in Working Capital | (4.4M) | 28.08M | 5.06M | 32.04M | (51.06M) |
| Accounts Receivables | (19.75M) | 15.17M | 15.33M | (2.97M) | (134.72M) |
| Inventory | 19.75M | 0 | 0 | 0 | (25.31M) |
| Accounts Payables | 2.83M | (349K) | 2.78M | 1.51M | 26.61M |
| Other Working Capital | (7.23M) | 13.26M | (13.05M) | 33.5M | 82.36M |
| Other Non-Cash Items | 18.5M | (61.25M) | 103.93M | (111.3M) | 191.63M |
| Operating Cash Flow | (497.93M) | (419.49M) | (527.72M) | (520.73M) | (445.91M) |
| Capital Expenditures | (48.25M) | (6.32M) | (1.31M) | (933K) | (1.1M) |
| Acquisitions (Net) | (35M) | 0 | 0 | (140K) | 0 |
| Purchases of Investments | (643.28M) | (193.06M) | (137.26M) | (88.4M) | (28.2M) |
| Sales of Investments | 477.04M | 532.52M | 193.11M | 158.23M | 11M |
| Other Investing Activities | 48.65M | 118.5M | (503K) | (7.98M) | (6.19M) |
| Investing Cash Flow | (200.83M) | 453.15M | 54.03M | 60.78M | (24.49M) |
| Debt Repayment | 1.08B | (20.49M) | 0 | 476.58M | 385.5M |
| Common Stock Issued | 0 | 4.85M | 449.81M | 314.74M | 34.15M |
| Common Stock Repurchased | (204.75M) | (1.56M) | (6.88M) | (7.53M) | (48.28M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (138.49M) | 4.06M | 8.61M | (35.34M) | (12.08M) |
| Financing Cash Flow | 736.45M | (13.13M) | 451.54M | 748.46M | 359.29M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 37.69M | 20.52M | (22.15M) | 288.51M | (111.1M) |
| Free Cash Flow | (546.18M) | (425.82M) | (529.03M) | (521.66M) | (447.01M) |
BridgeBio Pharma, Inc.
NASDAQ:BBIO
Intrinsic Alpha fair value
Locked
Current Price
$78.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.